Having trouble accessing articles? Reset your cache.

Novartis’ ofatumumab data comparable to Ocrevus in RRMS

Roche’s blockbuster MS therapy Ocrevus ocrelizumab could soon have company in relapsing-remitting multiple sclerosis as Phase III data presented Friday for ofatumumab by Novartis show the two anti-CD20 mAbs could have comparable efficacy.

Data from the ASCLEPIOS

Read the full 362 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers